A phase II open label study of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelium who have progressed <12 months after a previous platinum based chemotherapy.

Trial Profile

A phase II open label study of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelium who have progressed <12 months after a previous platinum based chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Jun 2015 Results for safety presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Results for efficacy presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Primary endpoint has not been met. (Objective clinical response rate of ≥20%)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top